Filing summary
Entity and period: The supplied metadata identifies Assembly Biosciences, Inc., but the filing itself is a Form 10-Q for Ventrus BioSciences, Inc., a development-stage specialty pharmaceutical company, for the quarter and nine months ended September 30, 2011. Investors should verify the issuer and filing identity before relying on this summary.
Financial performance and position
- Revenue: No product-sales revenue to date; the filing reports no revenue line or product sales. Products had not received FDA or other regulatory approval.
- Quarter ended September 30, 2011: R&D expense was $3.67 million; G&A was $1.88 million; operating loss was $5.55 million; net loss was $5.80 million, or $0.50 per share.
- Nine months ended September 30, 2011: R&D expense was $7.74 million; G&A was $7.38 million; operating loss was $15.11 million; net loss was $15.49 million, or $1.79 per share.
- Cash flow: Operating cash use was $8.74 million and investing cash use was $0.01 million for the first nine months. Financing provided $47.47 million, principally from the July 2011 offering. Cash increased $38.72 million to $53.29 million.
- Liquidity and debt: Current assets were $53.38 million and current liabilities were $1.18 million at September 30, 2011. Total liabilities were $1.18 million; borrowings and notes payable shown on the year-end balance sheet had been repaid, leaving no debt reported at quarter-end.
- Margins: Not meaningful because the company had no product revenue. Accumulated development-stage deficit was $48.67 million.
Changes versus prior comparable periods
- Third-quarter 2011 net loss increased from $1.78 million in third-quarter 2010; nine-month net loss increased from $5.92 million in the prior-year period. R&D and G&A rose substantially as operations and clinical development expanded after financing.
- R&D expense increased 1,798% for the quarter and 585% for the nine months. G&A increased approximately 492% and 1,398%, respectively. Management attributed the increases mainly to expanded development, public-company activity, and stock-based compensation.
- Interest expense declined 96% for the quarter and 94% for the nine months, primarily because convertible notes converted to common stock in connection with the December 2010 IPO.
- The July 2011 equity offering raised approximately $47.56 million net. The company used offering proceeds to repay the Paramount Credit Partners notes and other borrowings; the PCP repayment also triggered recognition of the remaining debt discount as interest expense.
Outlook, risks, and notable items
- Pipeline and milestones: VEN 309 (iferanserin) is in U.S. Phase III development; one of two planned pivotal trials began in August 2011. The company expected initial trial data in the first half of 2012 and stated an NDA could be submitted as early as 2014, subject to results and other factors. VEN 307 (diltiazem) was in a European Phase III trial, with data expected in the second quarter of 2012; management described possible U.S. trial paths and an NDA target in 2013.
- Funding outlook: Management said September 30 cash was expected to fund operating requirements into 2014, but the financial-statement note also says funds were sufficient for the next 12 months. These statements differ in stated horizon. The filing says further funding may be needed and is not committed; financing may be unavailable or dilutive, and shortfalls could force delays, scope reductions, or relinquishment of product rights.
- Development costs and commitments: Management estimated approximately $32 million for specified VEN 309 work, $14 million for VEN 307 work and related obligations, and $12 million to complete the iferanserin acquisition. It estimated total development/commercialization costs, excluding milestone payments, of approximately $40 million for VEN 309, $20 million for VEN 307, and $15 million for VEN 308. Estimates may change with trial progress and results.
- Acquisition and licensing: Ventrus had paid $500,000 toward acquiring all rights to iferanserin and expected to pay $12 million at closing, subject to stated conditions. The S.L.A. Pharma agreement includes potential milestones, development costs, royalties, and monthly payments; two diltiazem trial milestones were met and paid in the third quarter.
- Risks and unusual items: The company expected substantial continuing losses and rising R&D costs, with clinical, regulatory, manufacturing, intellectual-property, and financing uncertainties. Nine-month results included $2.17 million of employee/director stock-based compensation and $3.63 million of consultant stock-based payments. CEO and CFO market-capitalization bonuses of $250,000 each were paid in the third quarter after the first threshold was met.
- Controls: Management concluded disclosure controls were not effective at September 30, 2011 because previously identified material weaknesses remained. Remediation included formalized accounting-control procedures, hiring a full-time controller, and engaging an independent accounting firm to review procedures and test controls.
Key facts for investors to verify
- Confirm the issuer: the provided metadata says Assembly Biosciences, while the filing names Ventrus BioSciences, Inc.
- Reconcile management’s stated cash runway into 2014 with the note’s statement that cash covered the next 12 months; assess actual burn against trial and acquisition spending.
- Track VEN 309 and VEN 307 trial enrollment, results, regulatory requirements, and whether projected NDA timelines remain achievable.
- Confirm completion and conditions of the $12 million iferanserin rights acquisition, and update remaining license, milestone, royalty, and development obligations.
- Monitor financing needs, potential dilution, and remediation of the disclosed material weaknesses in financial reporting controls.